CN Patent

CN107898784B — 艾曲波帕乙醇胺在抗结核分枝杆菌感染中的应用

Assigned to TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE · Expires 2020-09-18 · 6y expired

What this patent protects

本发明提供了一种针对结核分枝杆菌(Mycobacterium tuberculosis，Mtb)中的亮氨酸氨肽酶(LAP)的化合物，该化合物为艾曲波帕乙醇胺，对结核分枝杆菌中的亮氨酸氨肽酶具有显著的抑制活性，因此本发明提供的化合物能够用来制备针对结核分枝杆菌中亮氨酸氨肽酶的小分子抑制剂，有望成为抗Mtb感染的潜在药物。

USPTO Abstract

本发明提供了一种针对结核分枝杆菌(Mycobacterium tuberculosis，Mtb)中的亮氨酸氨肽酶(LAP)的化合物，该化合物为艾曲波帕乙醇胺，对结核分枝杆菌中的亮氨酸氨肽酶具有显著的抑制活性，因此本发明提供的化合物能够用来制备针对结核分枝杆菌中亮氨酸氨肽酶的小分子抑制剂，有望成为抗Mtb感染的潜在药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN107898784B
Jurisdiction
CN
Classification
—
Expires
2020-09-18
Drug substance claim
No
Drug product claim
No
Assignee
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.